Regulatory

Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 22 Feb 2024: Hengrui Medicine’s SHR-A1912 ADC gets Fast Track status from FDA Hengrui Medicine’s innovative CD79b antibody-drug-conjugate (ADC) drug, SHR-A1912, receives fast-track designation from the FDA for treating relapsed/refractory […]

by Sandhya Ramalingam

Continue Reading

Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 27 Feb 2024: 9MW2821 Receives Fast Track Designation from FDA The FDA grants Fast Track Designation to 9MW2821, a new ADC drug by Mabwell, targeting Nectin-4 for advanced esophageal squamous […]

by Sandhya Ramalingam

Continue Reading